



BioQuanta and Gentronix announce commercial partnership covering commercialization of the Mitoxis[®] functional metabolic platform.

BioQuanta SA, a French company engaged in the implementation of predictive and personalized medicine and Gentronix Limited, the specialist genotoxicity assay provider, are pleased to announce the signing of a commercial agreement covering the commercialization of the Mitoxis[®] functional metabolomics platform from BioQuanta.

Under the terms of the agreement Gentronix will become a worldwide distributor of Mitoxis[®] services giving customers access to over 70 discrete assays central to a deeper understanding of cell health. This comprehensive range of assays covers key functional metabolisms important for the early detection of toxicity liabilities, including the electron-transport chain, oxidative stress, cellular energy status, inflammation and cell death.

Mitoxis[®] has been developed on highly automated analyzers used in clinical biology, and is different from systems based on microplate technology, thus delivers results with the unparalleled precision of clinical diagnostics. The speed and accuracy of the Mitoxis[®] approach allows the simultaneous analysis of many parameters (> 30) on the same reduced sample volume of < 5µl, with limited or no sample preparation. With an overall CV < 4%, inter-sample variability is lowered, leading to increased confidence in the results and a better understanding of inter-dependencies between parameters. Mitoxis[®] provides unmatched results to evaluate side effects of exogenous molecules (therapeutic, cosmetic or industrial) on the main transversal metabolic pathways of the cell.

The platform was developed to meet the same performance criteria of standard operating procedures in place for clinical biology and is the result of expertise gained from performing millions of tests per year routinely in a French public hospital.

Rémi Rabeuf, CEO at BioQuanta commented, *"We are pleased to conclude this agreement with Gentronix, given the synergies between our services and solutions contributing to improve the development of safer drugs and ultimately better patient management. This partnership will contribute to commercialize Mitoxis[®] internationally and expand our market access".*

Dr. Steve Beasley, Commercial Director at Gentronix said, *"This agreement allows Gentronix to further expand its range of services across all of the sectors we currently serve to provide our customers access to a wide range of cell health assays of unparalleled accuracy. We have an expanding customer base that will benefit from access to these highly accurate metabolomics assays".*

**About BioQuanta**

BioQuanta is a biotechnology company engaged in the implementation of predictive and personalized medicine. The company aims to become a major player in the biopharmaceutical R&D by contributing to the development of innovative drugs, and powerful diagnostic solutions to categorize patients. The BioQuanta's offer "*Science as a service*", including MultiDIP® *in silico* and Mitoxis® *in vitro* platforms, addresses health sciences, cosmetics, and industries involved in REACH sectors. The Company also applies its know-how to developing new biomarkers and diagnostic kits for life science, *in vitro* diagnostics and industrial applications.

BioQuanta enjoys a unique position in the core private/public business thanks to its close partnerships with academic and hospital. The Company is certified "Innovative Company" and listed on Euronext Paris, Marché Libre since July 2009 (ISIN code: FR0010775197 - Ticker: MLBQA)

www.bioquanta.net

contact@bioquanta.net

**About Gentronix Limited**

Gentronix provides services and solutions that help companies optimize the development of drugs and other chemicals, by reducing rates of attrition due to toxicity and ensuring safer products across a wide range of chemistry driven industries.

Our primary focus is on providing better hazard identification assays for genotoxicity through the use of our patented human cell GADD45a reporter assays GreenScreen HC® and BlueScreen HC™. Gentronix provides contract services for genotoxicity in these and related assays including Ames, Comet and Micronucleus tests, as well as a wide range of ADME and predictive toxicity endpoints.

www.gentronix.co.uk

info@gentronix.co.uk

**About Genopole®**

Genopole® is the leading French biopark dedicated to research in genetics and biotech for healthcare and the environment. It brings together 20 academic laboratories, 66 biotech companies and university teaching facilities. The biopark's objectives are to promote research in genomics, post-genomics & related sciences, transfer technology to industry, develop high- level life science teaching & training and foster the creation and growth of biotech companies.

www.genopole.fr

BIOQUANTA SA

Corporate Communication

Mr. Thierry Gérardi
thierry.gerardi@bioquanta.net
Ph: +33 (0)1 74 05 63 53

Scientific Communication

Dr LydieViatte
lydie.viatte@bioquanta.net
Ph: +33 (0)1 74 05 63 58

GENTRONIX LIMITED

Commercial Director

Dr Steve Beasley,
steve.beasley@gentronix.co.uk
Ph: +44 (0)161 603 7676,

Communication agency

Dr Catherine Butcher, *Barrett Dixon Bell Limited*
catherine@bdb.co.uk
Ph: +44 (0) 161 925 4700,

GENOPOLE®

Press Communication

Véronique Le Boulc'h
veronique.leboulch@genopole.fr
Ph: +33 (0)1 60 87 44 98